Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexverapamil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verapamil SCHEMBL29450374 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| (S)-Verapamil SCHEMBL29768846 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL30402443 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29450364 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29064783 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL16742 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL33297 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL1902363 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29440902 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| (S)-Verapamil SCHEMBL14874635 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360081-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | TRIASTEK INC (CN) | 2025-11-27 | — | — | US | claimed |
| EP-4604932-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2025-08-27 | — | — | EP | claimed |
| WO-2024083145-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2024-04-25 | — | — | WO | claimed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4705296-A1 | HETEROARYLINDOLE INHIBITORS OF APOL-1 | OmniAB, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-11358995-B2 | Compositions and methods of use for treating metabolic disorders | NGM BIOPHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022089631-A1 | DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2022-05-05 | — | — | WO | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2022076495-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220112181-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | US | disclosed |
| WO-2022076496-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3972589-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972590-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | CACNA1C 3846/4885CACNA1F 3527/4885CACNA1D 3931/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | CACNA1C 626/4885CACNA1F 1259/4885CACNA1D 903/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | CACNA1C 4096/4885CACNA1F 4372/4885CACNA1D 3925/4885 |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | CACNA1C 1705/4885CACNA1F 1587/4885CACNA1D 1569/4885 |
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | CACNA1C 3978/4885CACNA1F 3770/4885CACNA1D 4088/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | CACNA1C 3355/4885CACNA1F 3908/4885CACNA1D 3546/4885 |
| US-20220112181-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, MOGAT2 | CACNA1C 4520/4885CACNA1F 4513/4885CACNA1D 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.